China approves Wegovy for MASH, a first for GLP-1 drugs there

Chinese regulators have approved Wegovy (semaglutide) for metabolic dysfunction-associated steatohepatitis, or MASH, in non-cirrhotic adults with moderate to advanced fibrosis, stages F2 to F3. Novo Nordisk announced the decision on Sept. 10, 2026, saying the medicine is the first in the GLP-1 class cleared in China for the liver disease ^[1].

MASH is a severe form of fatty liver disease in which fat buildup inflames and scars the liver. In advanced stages it can progress to cirrhosis and liver failure ^[1]. China is one of the largest patient markets for the condition ^[1].

The approval extends Wegovy's label in China beyond weight management and cardiovascular risk reduction into liver health. Novo Nordisk framed the clearance as an expansion of the semaglutide evidence base, and it lands as competition in the obesity-drug market intensifies ^[1].

"The liver health-related benefits evidence extends the established evidence for Wegovy from weight management and cardiovascular health to liver health, further supporting its role in the comprehensive management of obesity and related complications," the company said in a statement ^[1].

Novo Nordisk markets the same treatment in Europe under the brand name Kayshild, and semaglutide is the active ingredient in both Wegovy and Kayshild ^[2]. The company's announcement did not include data on how much the drug reduced liver inflammation or scarring, and no effect sizes from that review have been reported ^[1].

Why it matters for patients

The decision applies to patients in China. It does not by itself change what Wegovy is cleared for in the United States, and no US filing or approval for a MASH indication for Wegovy has been reported ^[1]. For Americans with MASH, this announcement does not create a new access pathway, alter insurance coverage, or change the drug's US label ^[1].

Wegovy's US label, as described in the announcement, covers weight management and cardiovascular risk reduction rather than liver disease ^[1]. MASH is usually found through testing rather than symptoms, so a new approval in another country does not mean the condition is newly treatable where a patient lives ^[1].

One piece of context for US readers: approval in a major market can signal how a company plans to position a drug elsewhere, but Novo Nordisk has not said whether it will seek a MASH indication in the United States or Europe, and no timeline for such a step has been disclosed ^[1].

What happens next

No launch date for the MASH indication in China, no price, and no reimbursement plan have been disclosed ^[1]. Whether Chinese insurers or public programs would cover Wegovy for MASH has not been reported ^[1].

Novo Nordisk has also not said how the approval might affect supply of semaglutide in other markets, or whether the liver data behind the Chinese decision will be published in full ^[1]. The company's statement, reported on Sept. 10, 2026, described the evidence base but gave no trial results ^[1][2].

For US patients, the practical milestone to watch is whether Novo Nordisk files for a MASH indication with the Food and Drug Administration. No such filing has been disclosed ^[1]. Until then, the Chinese clearance stands as a regulatory change in one market rather than a shift in US care ^[1].